Department of Error (DOI:10.1016/S0140-6736(07)61295-1);Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial): an open-label randomised controlled study

Lancet

Volumn 370, Issue 9587, 2007, Pages 567-574

  Koo, Bon Kwon ^a   Kim, Yong Seok ^a   Park, Kyung Woo ^a   Yang, Han Mo ^a   Kwon, Dong A ^a   Chung, Jin Wook ^a   Hahn, Joo Yong ^a   Lee, Hae Young ^a   Park, Jin Shik ^a   Kang, Hyun Jae ^a   Cho, Young Seok ^b   Youn, Tae Jin ^b   Chung, Woo Young ^b   Chae, In Ho ^b   Choi, Dong Ju ^b   Oh, Byung Hee ^a   Park, Young Bae ^a   Kim, Hyo Soo ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CLOPIDOGREL;

ADULT; AGED; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DATA ANALYSIS; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; DRUG WITHDRAWAL; EXERCISE TEST; FEASIBILITY STUDY; FEMALE; GASTROINTESTINAL SYMPTOM; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; IN VITRO STUDY; INTERVENTION STUDY; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; RISK FACTOR; STATISTICAL ANALYSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT DURATION; TREATMENT PLANNING;

EID: 34547846004     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)61413-5     Document Type: Erratum

References (34)

1. Morice M., Serruys P., Sousa J., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346 (2002) 1773-1780
2. Stone G., Ellis S., Cox D., et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 15 (2004) 221-231
3. Cosgrave J., Agostoni P., Ge L., et al. Clinical outcome following aleatory implantation of paclitaxel-eluting or sirolimus-eluting stents in complex coronary lesions. Am J Cardiol 96 (2005) 1663-1668
4. Lemos P., van Mieghem C., Arampatzis C., et al. Post-sirolimus-eluting stent restenosis treated with repeat percutaneous intervention. Late angiographic and clinical outcomes. Circulation 109 (2004) 2500-2502
5. Stone G., Moses J., Ellis S., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
6. Steinbach G., Lynch P., Phillips R., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342 (2000) 1946-1952
7. Hara A., Yoshimi N., Niwa M., Ino M., and Mori H. Apoptosis induced by NS-398, a selective cyclooxygenase-2 inhibitor, in human colorectal cancer cell lines. Jpn J Cancer Res Sci 88 (1997) 600-604
8. Rahme E., Barkun A., Toubouti Y., et al. The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence. Gastroenterology 125 (2003) 404-412
9. Arico S., Pattingre S., Bauvy C., et al. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem 277 (2002) 27613-27621
10. Yang H., Kim H., Park K., et al. Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling. Circulation 110 (2004) 301-308
11. Wang K., Tarakji K., Zhou Z., et al. Celecoxib, a selective cyclooxygenase-2 inhibitor, decreases monocyte chemoattractant protein-1 expression and neointimal hyperplasia in the rabbit atherosclerotic balloon injury model. J Cardiovasc Pharmacol 45 (2005) 61-67
12. Bresalier R., Sandler R., Quan H., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 (2005) 1092-1102
13. Graham D., Campen D., Hui R., et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365 (2005) 475-481
14. McGettigan P., and Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase-2. JAMA 296 (2006) 1633-1644
15. Ellis S., Vandormael M., Cowley M., et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease: implications for patient selection. Circulation 82 (1990) 1193-1202
16. Cutlip D., Windecker S., Mehran R., et al. Clinical end points in coronary stent trials. A case for standardized definitions. Circulation 115 (2007) 2344-2351
17. Grube E., Silber S., Hauptmann K., et al. Six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 107 (2003) 38-42
18. Colombo A., Drzewiecki J., Banning A., et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 108 (2003) 788-794
19. Stone G., Ellis S., Cannon L., et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease. JAMA 294 (2005) 1215-1223
20. Kim Y., Park S., Lee C., et al. Comparison of sirolimus-eluting stent, paclitaxel-eluting stent, and bare metal stent in the treatment of long coronary lesions. Catheter Cardiovasc Interv 67 (2006) 181-187
21. Kim Y., Park S., Lee S., et al. Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease. Circulation 114 (2006) 2148-2153
22. Jang J., Hong M., Lee C., et al. Comparison between sirolimus- and paclitaxel-eluting stents for the treatment of chronic total occlusions. J Invasive Cardiol 18 (2006) 205-208
23. Win H., Caldera A., Maresh K., et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 297 (2007) 2001-2009
24. Pelliccia F., Pasceri V., Granatelli A., et al. Safety and efficacy of short-term celecoxib before elective percutaneous coronary intervention for stable angina pectoris. Am J Cardiol 98 (2006) 1461-1463
25. Bogaty P., Brophy J., Noel M., et al. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study. Circulation 110 (2004) 934-939
26. Chenevard R., Hurlimann D., Bechir M., et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 107 (2003) 405-409
27. Title L., Giddens K., McInerney M., McQueen M., and Nassar B. Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. J Am Coll Cardiol 42 (2003) 1747-1753
28. Niederberger E., Manderscheid C., Grösch S., Schmidt H., Ehnert C., and Geisslinger G. Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. Biochem Pharmacol 68 (2004) 341-350
29. Walter M., Jacob R., Day C., Dahlborg R., Weng Y., and Mason P. Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs. Atherosclerosis 177 (2004) 235-243
30. Bertagnolli M., Eagle C., Zauber A., et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355 (2006) 873-884
31. Wilner K., Rushing M., Walden C., et al. Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers. J Clin Pharmacol 42 (2002) 1027-1030
32. Renda G., Tacconelli S., Capone M., et al. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clin Pharmacol Ther 80 (2006) 264-274
33. Arber N., Eagle C., Spicak J., et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355 (2006) 885-895
34. Borgdorff P., Tangelder G., and Paulus W. Cyclooxygenase-2 inhibitors enhance shear stress-induced platelet aggregation. J Am Coll Cardiol 48 (2006) 817-823